Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPRINT: Selinexor in Solid Tumors, NSCLC, and CRC
NCT04256707Phase 2Completed
- Sponsor
- Karyopharm Therapeutics Inc.
- Start
- Feb 2020
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of selinexor in non-small cell lung cancer (NSCLC), colorectal cancer (CRC), solid tumor, sponsored by Karyopharm Therapeutics Inc.. Started Feb 2020; status: completed.
02
Drugs
selinexor
03
Conditions
non-small cell lung cancer (NSCLC)colorectal cancer (CRC)solid tumor
Beyond the preview
Go deeper on NCT04256707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04256707.